#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Diy_coref|
#T_RL=webanno.custom.Diy_coref_re|BT_webanno.custom.Diy_coref


#Text=[0556] By way of yet further illustration, and referring to U.S.
1-1	0-1	[	_	_	
1-2	1-5	0556	_	_	
1-3	5-6	]	_	_	
1-4	7-9	By	_	_	
1-5	10-13	way	_	_	
1-6	14-16	of	_	_	
1-7	17-20	yet	_	_	
1-8	21-28	further	_	_	
1-9	29-41	illustration	_	_	
1-10	41-42	,	_	_	
1-11	43-46	and	_	_	
1-12	47-56	referring	_	_	
1-13	57-59	to	_	_	
1-14	60-63	U.S	_	_	
1-15	63-64	.	_	_	

#Text=Pat.
2-1	65-68	Pat	_	_	
2-2	68-69	.	_	_	

#Text=No. 4,916,193 (the entire disclosure of which is hereby incorporated by reference into this specification), the polymeric material may be a copolymer containing carbonate repeat units and ester repeat units (see, e.g., claim 1 of the patent).
3-1	70-72	No	_	_	
3-2	72-73	.	_	_	
3-3	74-83	4,916,193	_	_	
3-4	84-85	(	_	_	
3-5	85-88	the	_	_	
3-6	89-95	entire	_	_	
3-7	96-106	disclosure	_	_	
3-8	107-109	of	_	_	
3-9	110-115	which	_	_	
3-10	116-118	is	_	_	
3-11	119-125	hereby	_	_	
3-12	126-138	incorporated	_	_	
3-13	139-141	by	_	_	
3-14	142-151	reference	_	_	
3-15	152-156	into	_	_	
3-16	157-161	this	_	_	
3-17	162-175	specification	_	_	
3-18	175-176	)	_	_	
3-19	176-177	,	_	_	
3-20	178-181	the	_	_	
3-21	182-191	polymeric	_	_	
3-22	192-200	material	_	_	
3-23	201-204	may	_	_	
3-24	205-207	be	_	_	
3-25	208-209	a	_	_	
3-26	210-219	copolymer	_	_	
3-27	220-230	containing	_	_	
3-28	231-240	carbonate	_	_	
3-29	241-247	repeat	_	_	
3-30	248-253	units	_	_	
3-31	254-257	and	_	_	
3-32	258-263	ester	_	_	
3-33	264-270	repeat	_	_	
3-34	271-276	units	_	_	
3-35	277-278	(	_	_	
3-36	278-281	see	_	_	
3-37	281-282	,	_	_	
3-38	283-286	e.g	_	_	
3-39	286-287	.	_	_	
3-40	287-288	,	_	_	
3-41	289-294	claim	_	_	
3-42	295-296	1	_	_	
3-43	297-299	of	_	_	
3-44	300-303	the	_	_	
3-45	304-310	patent	_	_	
3-46	310-311	)	_	_	
3-47	311-312	.	_	_	

#Text=As disclosed in column 2 of the patent, it may also be "collagen," "homopolymers and copolymers of glycolic acid and lactic acid," "alpha-hydroxy carboxylic acids in conjunction with Krebs cycle dicarboxylic acids and aliphatic diols," "polycarbonate-containing polymers," and "high molecular weight fiber-forming crystalline copolymers of lactide and glycolide."
4-1	313-315	As	_	_	
4-2	316-325	disclosed	_	_	
4-3	326-328	in	_	_	
4-4	329-335	column	_	_	
4-5	336-337	2	_	_	
4-6	338-340	of	_	_	
4-7	341-344	the	_	_	
4-8	345-351	patent	_	_	
4-9	351-352	,	_	_	
4-10	353-355	it	_	_	
4-11	356-359	may	_	_	
4-12	360-364	also	_	_	
4-13	365-367	be	_	_	
4-14	368-369	"	_	_	
4-15	369-377	collagen	_	_	
4-16	377-378	,	_	_	
4-17	378-379	"	_	_	
4-18	380-381	"	_	_	
4-19	381-393	homopolymers	_	_	
4-20	394-397	and	_	_	
4-21	398-408	copolymers	_	_	
4-22	409-411	of	_	_	
4-23	412-420	glycolic	_	_	
4-24	421-425	acid	_	_	
4-25	426-429	and	_	_	
4-26	430-436	lactic	_	_	
4-27	437-441	acid	_	_	
4-28	441-442	,	_	_	
4-29	442-443	"	_	_	
4-30	444-445	"	_	_	
4-31	445-458	alpha-hydroxy	_	_	
4-32	459-469	carboxylic	_	_	
4-33	470-475	acids	_	_	
4-34	476-478	in	_	_	
4-35	479-490	conjunction	_	_	
4-36	491-495	with	_	_	
4-37	496-501	Krebs	_	_	
4-38	502-507	cycle	_	_	
4-39	508-520	dicarboxylic	_	_	
4-40	521-526	acids	_	_	
4-41	527-530	and	_	_	
4-42	531-540	aliphatic	_	_	
4-43	541-546	diols	_	_	
4-44	546-547	,	_	_	
4-45	547-548	"	_	_	
4-46	549-550	"	_	_	
4-47	550-574	polycarbonate-containing	_	_	
4-48	575-583	polymers	_	_	
4-49	583-584	,	_	_	
4-50	584-585	"	_	_	
4-51	586-589	and	_	_	
4-52	590-591	"	_	_	
4-53	591-595	high	_	_	
4-54	596-605	molecular	_	_	
4-55	606-612	weight	_	_	
4-56	613-626	fiber-forming	_	_	
4-57	627-638	crystalline	_	_	
4-58	639-649	copolymers	_	_	
4-59	650-652	of	_	_	
4-60	653-660	lactide	_	_	
4-61	661-664	and	_	_	
4-62	665-674	glycolide	_	_	
4-63	674-675	.	_	_	
4-64	675-676	"	_	_	

#Text=Thus, it is disclosed in such column 2 that: "Various polymers have been proposed for use in the fabrication of bioresorbable medical devices.
5-1	677-681	Thus	_	_	
5-2	681-682	,	_	_	
5-3	683-685	it	_	_	
5-4	686-688	is	_	_	
5-5	689-698	disclosed	_	_	
5-6	699-701	in	_	_	
5-7	702-706	such	_	_	
5-8	707-713	column	_	_	
5-9	714-715	2	_	_	
5-10	716-720	that	_	_	
5-11	720-721	:	_	_	
5-12	722-723	"	_	_	
5-13	723-730	Various	_	_	
5-14	731-739	polymers	_	_	
5-15	740-744	have	_	_	
5-16	745-749	been	_	_	
5-17	750-758	proposed	_	_	
5-18	759-762	for	_	_	
5-19	763-766	use	_	_	
5-20	767-769	in	_	_	
5-21	770-773	the	_	_	
5-22	774-785	fabrication	_	_	
5-23	786-788	of	_	_	
5-24	789-802	bioresorbable	_	_	
5-25	803-810	medical	_	_	
5-26	811-818	devices	_	_	
5-27	818-819	.	_	_	

#Text=Examples of absorbable materials used in nerve repair include collagen as disclosed by D.
6-1	820-828	Examples	_	_	
6-2	829-831	of	_	_	
6-3	832-842	absorbable	_	_	
6-4	843-852	materials	_	_	
6-5	853-857	used	_	_	
6-6	858-860	in	_	_	
6-7	861-866	nerve	_	_	
6-8	867-873	repair	_	_	
6-9	874-881	include	_	_	
6-10	882-890	collagen	_	_	
6-11	891-893	as	_	_	
6-12	894-903	disclosed	_	_	
6-13	904-906	by	_	_	
6-14	907-908	D	_	_	
6-15	908-909	.	_	_	

#Text=G.
7-1	910-911	G	_	_	
7-2	911-912	.	_	_	

#Text=Kline and G.
8-1	913-918	Kline	_	_	
8-2	919-922	and	_	_	
8-3	923-924	G	_	_	
8-4	924-925	.	_	_	

#Text=J.
9-1	926-927	J	_	_	
9-2	927-928	.	_	_	

#Text=Hayes, "The Use of a Resorbable Wrapper for Peripheral Nerve Repair, Experimental Studies in Chimpanzees", J.
10-1	929-934	Hayes	_	_	
10-2	934-935	,	_	_	
10-3	936-937	"	_	_	
10-4	937-940	The	_	_	
10-5	941-944	Use	_	_	
10-6	945-947	of	_	_	
10-7	948-949	a	_	_	
10-8	950-960	Resorbable	_	_	
10-9	961-968	Wrapper	_	_	
10-10	969-972	for	_	_	
10-11	973-983	Peripheral	_	_	
10-12	984-989	Nerve	_	_	
10-13	990-996	Repair	_	_	
10-14	996-997	,	_	_	
10-15	998-1010	Experimental	_	_	
10-16	1011-1018	Studies	_	_	
10-17	1019-1021	in	_	_	
10-18	1022-1033	Chimpanzees	_	_	
10-19	1033-1034	"	_	_	
10-20	1034-1035	,	_	_	
10-21	1036-1037	J	_	_	
10-22	1037-1038	.	_	_	

#Text=Neurosurgery 21, 737 (1964).
11-1	1039-1051	Neurosurgery	_	_	
11-2	1052-1054	21	_	_	
11-3	1054-1055	,	_	_	
11-4	1056-1059	737	_	_	
11-5	1060-1061	(	_	_	
11-6	1061-1065	1964	_	_	
11-7	1065-1066	)	_	_	
11-8	1066-1067	.	_	_	

#Text=Artandi et al., U.S.
12-1	1068-1075	Artandi	_	_	
12-2	1076-1078	et	_	_	
12-3	1079-1081	al	_	_	
12-4	1081-1082	.	_	_	
12-5	1082-1083	,	_	_	
12-6	1084-1087	U.S	_	_	
12-7	1087-1088	.	_	_	

#Text=Pat.
13-1	1089-1092	Pat	_	_	
13-2	1092-1093	.	_	_	

#Text=No. 3,272,204 (1966) reports the use of collagen protheses that are reinforced with nonabsorbable fabrics.
14-1	1094-1096	No	_	_	
14-2	1096-1097	.	_	_	
14-3	1098-1107	3,272,204	_	_	
14-4	1108-1109	(	_	_	
14-5	1109-1113	1966	_	_	
14-6	1113-1114	)	_	_	
14-7	1115-1122	reports	_	_	
14-8	1123-1126	the	_	_	
14-9	1127-1130	use	_	_	
14-10	1131-1133	of	_	_	
14-11	1134-1142	collagen	_	_	
14-12	1143-1152	protheses	_	_	
14-13	1153-1157	that	_	_	
14-14	1158-1161	are	_	_	
14-15	1162-1172	reinforced	_	_	
14-16	1173-1177	with	_	_	
14-17	1178-1191	nonabsorbable	_	_	
14-18	1192-1199	fabrics	_	_	
14-19	1199-1200	.	_	_	

#Text=These articles are intended to be placed permanently in a human body.
15-1	1201-1206	These	_	_	
15-2	1207-1215	articles	_	_	
15-3	1216-1219	are	_	_	
15-4	1220-1228	intended	_	_	
15-5	1229-1231	to	_	_	
15-6	1232-1234	be	_	_	
15-7	1235-1241	placed	_	_	
15-8	1242-1253	permanently	_	_	
15-9	1254-1256	in	_	_	
15-10	1257-1258	a	_	_	
15-11	1259-1264	human	_	_	
15-12	1265-1269	body	_	_	
15-13	1269-1270	.	_	_	

#Text=However, one of the disadvantages inherent with collagenous materials, whether utilized alone or in conjunction with biodurable materials, is their potential antigenicity.
16-1	1271-1278	However	_	_	
16-2	1278-1279	,	_	_	
16-3	1280-1283	one	_	_	
16-4	1284-1286	of	_	_	
16-5	1287-1290	the	_	_	
16-6	1291-1304	disadvantages	_	_	
16-7	1305-1313	inherent	_	_	
16-8	1314-1318	with	_	_	
16-9	1319-1330	collagenous	_	_	
16-10	1331-1340	materials	_	_	
16-11	1340-1341	,	_	_	
16-12	1342-1349	whether	_	_	
16-13	1350-1358	utilized	_	_	
16-14	1359-1364	alone	_	_	
16-15	1365-1367	or	_	_	
16-16	1368-1370	in	_	_	
16-17	1371-1382	conjunction	_	_	
16-18	1383-1387	with	_	_	
16-19	1388-1398	biodurable	_	_	
16-20	1399-1408	materials	_	_	
16-21	1408-1409	,	_	_	
16-22	1410-1412	is	_	_	
16-23	1413-1418	their	_	_	
16-24	1419-1428	potential	_	_	
16-25	1429-1441	antigenicity	_	_	
16-26	1441-1442	.	_	_	

#Text=Other biodegradable polymers of particular interest for medical implantation purposes are homopolymers and copolymers of glycolic acid and lactic acid.
17-1	1443-1448	Other	_	_	
17-2	1449-1462	biodegradable	_	_	
17-3	1463-1471	polymers	_	_	
17-4	1472-1474	of	_	_	
17-5	1475-1485	particular	_	_	
17-6	1486-1494	interest	_	_	
17-7	1495-1498	for	_	_	
17-8	1499-1506	medical	_	_	
17-9	1507-1519	implantation	_	_	
17-10	1520-1528	purposes	_	_	
17-11	1529-1532	are	_	_	
17-12	1533-1545	homopolymers	_	_	
17-13	1546-1549	and	_	_	
17-14	1550-1560	copolymers	_	_	
17-15	1561-1563	of	_	_	
17-16	1564-1572	glycolic	_	_	
17-17	1573-1577	acid	_	_	
17-18	1578-1581	and	_	_	
17-19	1582-1588	lactic	_	_	
17-20	1589-1593	acid	_	_	
17-21	1593-1594	.	_	_	

#Text=A nerve cuff in the form of a smooth, rigid tube has been fabricated from a copolymer of lactic and glycolic acids [The Hand; 10 (3) 259 (1978)].
18-1	1595-1596	A	_	_	
18-2	1597-1602	nerve	_	_	
18-3	1603-1607	cuff	_	_	
18-4	1608-1610	in	_	_	
18-5	1611-1614	the	_	_	
18-6	1615-1619	form	_	_	
18-7	1620-1622	of	_	_	
18-8	1623-1624	a	_	_	
18-9	1625-1631	smooth	_	_	
18-10	1631-1632	,	_	_	
18-11	1633-1638	rigid	_	_	
18-12	1639-1643	tube	_	_	
18-13	1644-1647	has	_	_	
18-14	1648-1652	been	_	_	
18-15	1653-1663	fabricated	_	_	
18-16	1664-1668	from	_	_	
18-17	1669-1670	a	_	_	
18-18	1671-1680	copolymer	_	_	
18-19	1681-1683	of	_	_	
18-20	1684-1690	lactic	_	_	
18-21	1691-1694	and	_	_	
18-22	1695-1703	glycolic	_	_	
18-23	1704-1709	acids	_	_	
18-24	1710-1711	[	_	_	
18-25	1711-1714	The	_	_	
18-26	1715-1719	Hand	_	_	
18-27	1719-1720	;	_	_	
18-28	1721-1723	10	_	_	
18-29	1724-1725	(	_	_	
18-30	1725-1726	3	_	_	
18-31	1726-1727	)	_	_	
18-32	1728-1731	259	_	_	
18-33	1732-1733	(	_	_	
18-34	1733-1737	1978	_	_	
18-35	1737-1738	)	_	_	
18-36	1738-1739	]	_	_	
18-37	1739-1740	.	_	_	

#Text=European patent application No. 118-458-A discloses biodegradable materials used in organ protheses or artificial skin based on poly-L-lactic acid and/or poly-DL-lactic acid and polyester or polyether urethanes.
19-1	1741-1749	European	_	_	
19-2	1750-1756	patent	_	_	
19-3	1757-1768	application	_	_	
19-4	1769-1771	No	_	_	
19-5	1771-1772	.	_	_	
19-6	1773-1776	118	_	_	
19-7	1776-1777	-	_	_	
19-8	1777-1780	458	_	_	
19-9	1780-1781	-	_	_	
19-10	1781-1782	A	_	_	
19-11	1783-1792	discloses	_	_	
19-12	1793-1806	biodegradable	_	_	
19-13	1807-1816	materials	_	_	
19-14	1817-1821	used	_	_	
19-15	1822-1824	in	_	_	
19-16	1825-1830	organ	_	_	
19-17	1831-1840	protheses	_	_	
19-18	1841-1843	or	_	_	
19-19	1844-1854	artificial	_	_	
19-20	1855-1859	skin	_	_	
19-21	1860-1865	based	_	_	
19-22	1866-1868	on	_	_	
19-23	1869-1882	poly-L-lactic	_	_	
19-24	1883-1887	acid	_	_	
19-25	1888-1891	and	_	_	
19-26	1891-1892	/	_	_	
19-27	1892-1894	or	_	_	
19-28	1895-1909	poly-DL-lactic	_	_	
19-29	1910-1914	acid	_	_	
19-30	1915-1918	and	_	_	
19-31	1919-1928	polyester	_	_	
19-32	1929-1931	or	_	_	
19-33	1932-1941	polyether	_	_	
19-34	1942-1951	urethanes	_	_	
19-35	1951-1952	.	_	_	

#Text=U.S.
20-1	1953-1956	U.S	_	_	
20-2	1956-1957	.	_	_	

#Text=Pat.
21-1	1958-1961	Pat	_	_	
21-2	1961-1962	.	_	_	

#Text=No. 4,481,353 discloses bioresorbable polyester polymers, and composites containing these polymers, that are also made up of alpha-hydroxy carboxylic acids, in conjunction with Krebs cycle dicarboxylic acids and aliphatic diols.
22-1	1963-1965	No	_	_	
22-2	1965-1966	.	_	_	
22-3	1967-1976	4,481,353	_	_	
22-4	1977-1986	discloses	_	_	
22-5	1987-2000	bioresorbable	_	_	
22-6	2001-2010	polyester	_	_	
22-7	2011-2019	polymers	_	_	
22-8	2019-2020	,	_	_	
22-9	2021-2024	and	_	_	
22-10	2025-2035	composites	_	_	
22-11	2036-2046	containing	_	_	
22-12	2047-2052	these	_	_	
22-13	2053-2061	polymers	_	_	
22-14	2061-2062	,	_	_	
22-15	2063-2067	that	_	_	
22-16	2068-2071	are	_	_	
22-17	2072-2076	also	_	_	
22-18	2077-2081	made	_	_	
22-19	2082-2084	up	_	_	
22-20	2085-2087	of	_	_	
22-21	2088-2101	alpha-hydroxy	_	_	
22-22	2102-2112	carboxylic	_	_	
22-23	2113-2118	acids	_	_	
22-24	2118-2119	,	_	_	
22-25	2120-2122	in	_	_	
22-26	2123-2134	conjunction	_	_	
22-27	2135-2139	with	_	_	
22-28	2140-2145	Krebs	_	_	
22-29	2146-2151	cycle	_	_	
22-30	2152-2164	dicarboxylic	_	_	
22-31	2165-2170	acids	_	_	
22-32	2171-2174	and	_	_	
22-33	2175-2184	aliphatic	_	_	
22-34	2185-2190	diols	_	_	
22-35	2190-2191	.	_	_	

#Text=These polyesters are useful in fabricating nerve guidance channels as well as other surgical articles such as sutures and ligatures.
23-1	2192-2197	These	_	_	
23-2	2198-2208	polyesters	_	_	
23-3	2209-2212	are	_	_	
23-4	2213-2219	useful	_	_	
23-5	2220-2222	in	_	_	
23-6	2223-2234	fabricating	_	_	
23-7	2235-2240	nerve	_	_	
23-8	2241-2249	guidance	_	_	
23-9	2250-2258	channels	_	_	
23-10	2259-2261	as	_	_	
23-11	2262-2266	well	_	_	
23-12	2267-2269	as	_	_	
23-13	2270-2275	other	_	_	
23-14	2276-2284	surgical	_	_	
23-15	2285-2293	articles	_	_	
23-16	2294-2298	such	_	_	
23-17	2299-2301	as	_	_	
23-18	2302-2309	sutures	_	_	
23-19	2310-2313	and	_	_	
23-20	2314-2323	ligatures	_	_	
23-21	2323-2324	.	_	_	

#Text=U.S.
24-1	2325-2328	U.S	_	_	
24-2	2328-2329	.	_	_	

#Text=Pat.
25-1	2330-2333	Pat	_	_	
25-2	2333-2334	.	_	_	

#Text=Nos. 4,243,775 and 4,429,080 disclose the use of polycarbonate-containing polymers in certain medical applications, especially sutures, ligatures and haemostatic devices.
26-1	2335-2338	Nos	_	_	
26-2	2338-2339	.	_	_	
26-3	2340-2349	4,243,775	_	_	
26-4	2350-2353	and	_	_	
26-5	2354-2363	4,429,080	_	_	
26-6	2364-2372	disclose	_	_	
26-7	2373-2376	the	_	_	
26-8	2377-2380	use	_	_	
26-9	2381-2383	of	_	_	
26-10	2384-2408	polycarbonate-containing	_	_	
26-11	2409-2417	polymers	_	_	
26-12	2418-2420	in	_	_	
26-13	2421-2428	certain	_	_	
26-14	2429-2436	medical	_	_	
26-15	2437-2449	applications	_	_	
26-16	2449-2450	,	_	_	
26-17	2451-2461	especially	_	_	
26-18	2462-2469	sutures	_	_	
26-19	2469-2470	,	_	_	
26-20	2471-2480	ligatures	_	_	
26-21	2481-2484	and	_	_	
26-22	2485-2496	haemostatic	_	_	
26-23	2497-2504	devices	_	_	
26-24	2504-2505	.	_	_	

#Text=However, this disclosure is clearly limited only to "AB" and "ABA" type block copolymers where only the "B" block contains poly(trimethylene carbonate) or a random copolymer of glycolide with trimethylene carbonate and the "A" block is necessarily limited to glycolide.
27-1	2506-2513	However	_	_	
27-2	2513-2514	,	_	_	
27-3	2515-2519	this	_	_	
27-4	2520-2530	disclosure	_	_	
27-5	2531-2533	is	_	_	
27-6	2534-2541	clearly	_	_	
27-7	2542-2549	limited	_	_	
27-8	2550-2554	only	_	_	
27-9	2555-2557	to	_	_	
27-10	2558-2559	"	_	_	
27-11	2559-2561	AB	_	_	
27-12	2561-2562	"	_	_	
27-13	2563-2566	and	_	_	
27-14	2567-2568	"	_	_	
27-15	2568-2571	ABA	_	_	
27-16	2571-2572	"	_	_	
27-17	2573-2577	type	_	_	
27-18	2578-2583	block	_	_	
27-19	2584-2594	copolymers	_	_	
27-20	2595-2600	where	_	_	
27-21	2601-2605	only	_	_	
27-22	2606-2609	the	_	_	
27-23	2610-2611	"	_	_	
27-24	2611-2612	B	_	_	
27-25	2612-2613	"	_	_	
27-26	2614-2619	block	_	_	
27-27	2620-2628	contains	_	_	
27-28	2629-2633	poly	_	_	
27-29	2633-2634	(	_	_	
27-30	2634-2646	trimethylene	_	_	
27-31	2647-2656	carbonate	_	_	
27-32	2656-2657	)	_	_	
27-33	2658-2660	or	_	_	
27-34	2661-2662	a	_	_	
27-35	2663-2669	random	_	_	
27-36	2670-2679	copolymer	_	_	
27-37	2680-2682	of	_	_	
27-38	2683-2692	glycolide	_	_	
27-39	2693-2697	with	_	_	
27-40	2698-2710	trimethylene	_	_	
27-41	2711-2720	carbonate	_	_	
27-42	2721-2724	and	_	_	
27-43	2725-2728	the	_	_	
27-44	2729-2730	"	_	_	
27-45	2730-2731	A	_	_	
27-46	2731-2732	"	_	_	
27-47	2733-2738	block	_	_	
27-48	2739-2741	is	_	_	
27-49	2742-2753	necessarily	_	_	
27-50	2754-2761	limited	_	_	
27-51	2762-2764	to	_	_	
27-52	2765-2774	glycolide	_	_	
27-53	2774-2775	.	_	_	

#Text=In the copolymers of this patent, the dominant portion of the polymer is the glycolide component.
28-1	2776-2778	In	_	_	
28-2	2779-2782	the	_	_	
28-3	2783-2793	copolymers	_	_	
28-4	2794-2796	of	_	_	
28-5	2797-2801	this	_	_	
28-6	2802-2808	patent	_	_	
28-7	2808-2809	,	_	_	
28-8	2810-2813	the	_	_	
28-9	2814-2822	dominant	_	_	
28-10	2823-2830	portion	_	_	
28-11	2831-2833	of	_	_	
28-12	2834-2837	the	_	_	
28-13	2838-2845	polymer	_	_	
28-14	2846-2848	is	_	_	
28-15	2849-2852	the	_	_	
28-16	2853-2862	glycolide	_	_	
28-17	2863-2872	component	_	_	
28-18	2872-2873	.	_	_	

#Text=U.S.
29-1	2874-2877	U.S	_	_	
29-2	2877-2878	.	_	_	

#Text=Pat.
30-1	2879-2882	Pat	_	_	
30-2	2882-2883	.	_	_	

#Text=No. 4,157,437 discloses high molecular weight, fiber-forming crystalline copolymers of lactide and glycolide which are disclosed as useful in the preparation of absorbable surgical sutures.
31-1	2884-2886	No	_	_	
31-2	2886-2887	.	_	_	
31-3	2888-2897	4,157,437	_	_	
31-4	2898-2907	discloses	_	_	
31-5	2908-2912	high	_	_	
31-6	2913-2922	molecular	_	_	
31-7	2923-2929	weight	_	_	
31-8	2929-2930	,	_	_	
31-9	2931-2944	fiber-forming	_	_	
31-10	2945-2956	crystalline	_	_	
31-11	2957-2967	copolymers	_	_	
31-12	2968-2970	of	_	_	
31-13	2971-2978	lactide	_	_	
31-14	2979-2982	and	_	_	
31-15	2983-2992	glycolide	_	_	
31-16	2993-2998	which	_	_	
31-17	2999-3002	are	_	_	
31-18	3003-3012	disclosed	_	_	
31-19	3013-3015	as	_	_	
31-20	3016-3022	useful	_	_	
31-21	3023-3025	in	_	_	
31-22	3026-3029	the	_	_	
31-23	3030-3041	preparation	_	_	
31-24	3042-3044	of	_	_	
31-25	3045-3055	absorbable	_	_	
31-26	3056-3064	surgical	_	_	
31-27	3065-3072	sutures	_	_	
31-28	3072-3073	.	_	_	

#Text=The copolymers of this patent contain from about 50 to 75 wt. % of recurring units derived from glycolide."
#Text=[0557] By way of further illustration, and referring to U.S.
32-1	3074-3077	The	_	_	
32-2	3078-3088	copolymers	_	_	
32-3	3089-3091	of	_	_	
32-4	3092-3096	this	_	_	
32-5	3097-3103	patent	_	_	
32-6	3104-3111	contain	_	_	
32-7	3112-3116	from	_	_	
32-8	3117-3122	about	_	_	
32-9	3123-3125	50	_	_	
32-10	3126-3128	to	_	_	
32-11	3129-3131	75	_	_	
32-12	3132-3134	wt	_	_	
32-13	3134-3135	.	_	_	
32-14	3136-3137	%	_	_	
32-15	3138-3140	of	_	_	
32-16	3141-3150	recurring	_	_	
32-17	3151-3156	units	_	_	
32-18	3157-3164	derived	_	_	
32-19	3165-3169	from	_	_	
32-20	3170-3179	glycolide	_	_	
32-21	3179-3180	.	_	_	
32-22	3180-3181	"	_	_	
32-23	3182-3183	[	_	_	
32-24	3183-3187	0557	_	_	
32-25	3187-3188	]	_	_	
32-26	3189-3191	By	_	_	
32-27	3192-3195	way	_	_	
32-28	3196-3198	of	_	_	
32-29	3199-3206	further	_	_	
32-30	3207-3219	illustration	_	_	
32-31	3219-3220	,	_	_	
32-32	3221-3224	and	_	_	
32-33	3225-3234	referring	_	_	
32-34	3235-3237	to	_	_	
32-35	3238-3241	U.S	_	_	
32-36	3241-3242	.	_	_	

#Text=Pat.
33-1	3243-3246	Pat	_	_	
33-2	3246-3247	.	_	_	

#Text=No. 5,176,907 (the entire disclosure of which is hereby incorporated by reference into this specification), the polymeric material may be the poly-phosphoester-urethane) described and claimed in claim 1 of such patent.
34-1	3248-3250	No	_	_	
34-2	3250-3251	.	_	_	
34-3	3252-3261	5,176,907	_	_	
34-4	3262-3263	(	_	_	
34-5	3263-3266	the	_	_	
34-6	3267-3273	entire	_	_	
34-7	3274-3284	disclosure	_	_	
34-8	3285-3287	of	_	_	
34-9	3288-3293	which	_	_	
34-10	3294-3296	is	_	_	
34-11	3297-3303	hereby	_	_	
34-12	3304-3316	incorporated	_	_	
34-13	3317-3319	by	_	_	
34-14	3320-3329	reference	_	_	
34-15	3330-3334	into	_	_	
34-16	3335-3339	this	_	_	
34-17	3340-3353	specification	_	_	
34-18	3353-3354	)	_	_	
34-19	3354-3355	,	_	_	
34-20	3356-3359	the	_	_	
34-21	3360-3369	polymeric	_	_	
34-22	3370-3378	material	_	_	
34-23	3379-3382	may	_	_	
34-24	3383-3385	be	_	_	
34-25	3386-3389	the	_	_	
34-26	3390-3416	poly-phosphoester-urethane	_	_	
34-27	3416-3417	)	_	_	
34-28	3418-3427	described	_	_	
34-29	3428-3431	and	_	_	
34-30	3432-3439	claimed	_	_	
34-31	3440-3442	in	_	_	
34-32	3443-3448	claim	_	_	
34-33	3449-3450	1	_	_	
34-34	3451-3453	of	_	_	
34-35	3454-3458	such	_	_	
34-36	3459-3465	patent	_	_	
34-37	3465-3466	.	_	_	

#Text=Furthermore, the polymeric material may be one or more of the biodegradable polymers discussed in columns 1 and 2 of such patent.
35-1	3467-3478	Furthermore	_	_	
35-2	3478-3479	,	_	_	
35-3	3480-3483	the	_	_	
35-4	3484-3493	polymeric	_	_	
35-5	3494-3502	material	_	_	
35-6	3503-3506	may	_	_	
35-7	3507-3509	be	_	_	
35-8	3510-3513	one	_	_	
35-9	3514-3516	or	_	_	
35-10	3517-3521	more	_	_	
35-11	3522-3524	of	_	_	
35-12	3525-3528	the	_	_	
35-13	3529-3542	biodegradable	_	_	
35-14	3543-3551	polymers	_	_	
35-15	3552-3561	discussed	_	_	
35-16	3562-3564	in	_	_	
35-17	3565-3572	columns	_	_	
35-18	3573-3574	1	_	_	
35-19	3575-3578	and	_	_	
35-20	3579-3580	2	_	_	
35-21	3581-3583	of	_	_	
35-22	3584-3588	such	_	_	
35-23	3589-3595	patent	_	_	
35-24	3595-3596	.	_	_	

#Text=As is disclosed in such columns 1 and 2: "Polymers have been used as carriers of therapeutic agents to effect a localized and sustained release (Controlled Drug Delivery, Vol.
36-1	3597-3599	As	_	_	
36-2	3600-3602	is	_	_	
36-3	3603-3612	disclosed	_	_	
36-4	3613-3615	in	_	_	
36-5	3616-3620	such	_	_	
36-6	3621-3628	columns	_	_	
36-7	3629-3630	1	_	_	
36-8	3631-3634	and	_	_	
36-9	3635-3636	2	_	_	
36-10	3636-3637	:	_	_	
36-11	3638-3639	"	_	_	
36-12	3639-3647	Polymers	_	_	
36-13	3648-3652	have	_	_	
36-14	3653-3657	been	_	_	
36-15	3658-3662	used	_	_	
36-16	3663-3665	as	_	_	
36-17	3666-3674	carriers	_	_	
36-18	3675-3677	of	_	_	
36-19	3678-3689	therapeutic	_	_	
36-20	3690-3696	agents	_	_	
36-21	3697-3699	to	_	_	
36-22	3700-3706	effect	_	_	
36-23	3707-3708	a	_	_	
36-24	3709-3718	localized	_	_	
36-25	3719-3722	and	_	_	
36-26	3723-3732	sustained	_	_	
36-27	3733-3740	release	_	_	
36-28	3741-3742	(	_	_	
36-29	3742-3752	Controlled	_	_	
36-30	3753-3757	Drug	_	_	
36-31	3758-3766	Delivery	_	_	
36-32	3766-3767	,	_	_	
36-33	3768-3771	Vol	_	_	
36-34	3771-3772	.	_	_	

#Text=I and II, Bruck, S.
37-1	3773-3774	I	_	_	
37-2	3775-3778	and	_	_	
37-3	3779-3781	II	_	_	
37-4	3781-3782	,	_	_	
37-5	3783-3788	Bruck	_	_	
37-6	3788-3789	,	_	_	
37-7	3790-3791	S	_	_	
37-8	3791-3792	.	_	_	

#Text=D., (ed.), CRC Press, Boca Raton, Fla., 1983; Leong, et al., Adv.
38-1	3793-3794	D	_	_	
38-2	3794-3795	.	_	_	
38-3	3795-3796	,	_	_	
38-4	3797-3798	(	_	_	
38-5	3798-3800	ed	_	_	
38-6	3800-3801	.	_	_	
38-7	3801-3802	)	_	_	
38-8	3802-3803	,	_	_	
38-9	3804-3807	CRC	_	_	
38-10	3808-3813	Press	_	_	
38-11	3813-3814	,	_	_	
38-12	3815-3819	Boca	_	_	
38-13	3820-3825	Raton	_	_	
38-14	3825-3826	,	_	_	
38-15	3827-3830	Fla	_	_	
38-16	3830-3831	.	_	_	
38-17	3831-3832	,	_	_	
38-18	3833-3837	1983	_	_	
38-19	3837-3838	;	_	_	
38-20	3839-3844	Leong	_	_	
38-21	3844-3845	,	_	_	
38-22	3846-3848	et	_	_	
38-23	3849-3851	al	_	_	
38-24	3851-3852	.	_	_	
38-25	3852-3853	,	_	_	
38-26	3854-3857	Adv	_	_	
38-27	3857-3858	.	_	_	

#Text=Drug Delivery Review, 1:199, 1987).
39-1	3859-3863	Drug	_	_	
39-2	3864-3872	Delivery	_	_	
39-3	3873-3879	Review	_	_	
39-4	3879-3880	,	_	_	
39-5	3881-3882	1	_	_	
39-6	3882-3883	:	_	_	
39-7	3883-3886	199	_	_	
39-8	3886-3887	,	_	_	
39-9	3888-3892	1987	_	_	
39-10	3892-3893	)	_	_	
39-11	3893-3894	.	_	_	

#Text=These anti-mitotic compound delivery systems simulate infusion and offer the potential of enhanced therapeutic efficacy and reduced systemic toxicity."
40-1	3895-3900	These	_	_	
40-2	3901-3913	anti-mitotic	_	_	
40-3	3914-3922	compound	_	_	
40-4	3923-3931	delivery	_	_	
40-5	3932-3939	systems	_	_	
40-6	3940-3948	simulate	_	_	
40-7	3949-3957	infusion	_	_	
40-8	3958-3961	and	_	_	
40-9	3962-3967	offer	_	_	
40-10	3968-3971	the	_	_	
40-11	3972-3981	potential	_	_	
40-12	3982-3984	of	_	_	
40-13	3985-3993	enhanced	_	_	
40-14	3994-4005	therapeutic	_	_	
40-15	4006-4014	efficacy	_	_	
40-16	4015-4018	and	_	_	
40-17	4019-4026	reduced	_	_	
40-18	4027-4035	systemic	_	_	
40-19	4036-4044	toxicity	_	_	
40-20	4044-4045	.	_	_	
40-21	4045-4046	"	_	_	

#Text=The polymeric material may be such a poly-phosphoester-urethan- e.
#Text=[0558] U.S.
41-1	4047-4050	The	_	_	
41-2	4051-4060	polymeric	_	_	
41-3	4061-4069	material	_	_	
41-4	4070-4073	may	_	_	
41-5	4074-4076	be	_	_	
41-6	4077-4081	such	_	_	
41-7	4082-4083	a	_	_	
41-8	4084-4109	poly-phosphoester-urethan	_	_	
41-9	4109-4110	-	_	_	
41-10	4111-4112	e	_	_	
41-11	4112-4113	.	_	_	
41-12	4114-4115	[	_	_	
41-13	4115-4119	0558	_	_	
41-14	4119-4120	]	_	_	
41-15	4121-4124	U.S	_	_	
41-16	4124-4125	.	_	_	

#Text=Pat.
42-1	4126-4129	Pat	_	_	
42-2	4129-4130	.	_	_	

#Text=No. 5,176,907 also discloses "For a non-biodegradable matrix, the steps leading to release of the anti-mitotic compound are water diffusion into the matrix, dissolution of the therapeutic agent, and out-diffusion of the anti-mitotic compound through the channels of the matrix.
43-1	4131-4133	No	_	_	
43-2	4133-4134	.	_	_	
43-3	4135-4144	5,176,907	_	_	
43-4	4145-4149	also	_	_	
43-5	4150-4159	discloses	_	_	
43-6	4160-4161	"	_	_	
43-7	4161-4164	For	*[1]	47-1[2_1]	
43-8	4165-4166	a	*[1]	_	
43-9	4167-4184	non-biodegradable	*[1]	_	
43-10	4185-4191	matrix	*[1]	_	
43-11	4191-4192	,	*[1]	_	
43-12	4193-4196	the	*[1]	_	
43-13	4197-4202	steps	*[1]	_	
43-14	4203-4210	leading	*[1]	_	
43-15	4211-4213	to	*[1]	_	
43-16	4214-4221	release	*[1]	_	
43-17	4222-4224	of	*[1]	_	
43-18	4225-4228	the	*[1]	_	
43-19	4229-4241	anti-mitotic	*[1]	_	
43-20	4242-4250	compound	*[1]	_	
43-21	4251-4254	are	*[1]	_	
43-22	4255-4260	water	*[1]	_	
43-23	4261-4270	diffusion	*[1]	_	
43-24	4271-4275	into	*[1]	_	
43-25	4276-4279	the	*[1]	_	
43-26	4280-4286	matrix	*[1]	_	
43-27	4286-4287	,	*[1]	_	
43-28	4288-4299	dissolution	*[1]	_	
43-29	4300-4302	of	*[1]	_	
43-30	4303-4306	the	*[1]	_	
43-31	4307-4318	therapeutic	*[1]	_	
43-32	4319-4324	agent	*[1]	_	
43-33	4324-4325	,	*[1]	_	
43-34	4326-4329	and	*[1]	_	
43-35	4330-4343	out-diffusion	*[1]	_	
43-36	4344-4346	of	*[1]	_	
43-37	4347-4350	the	*[1]	_	
43-38	4351-4363	anti-mitotic	*[1]	_	
43-39	4364-4372	compound	*[1]	_	
43-40	4373-4380	through	*[1]	_	
43-41	4381-4384	the	*[1]	_	
43-42	4385-4393	channels	*[1]	_	
43-43	4394-4396	of	*[1]	_	
43-44	4397-4400	the	*[1]	_	
43-45	4401-4407	matrix	*[1]	_	
43-46	4407-4408	.	_	_	

#Text=As a consequence, the mean residence time of the anti-mitotic compound existing in the soluble state is longer for a non-biodegradable matrix than for a biodegradable matrix where a long passage through the channels is no longer required.
44-1	4409-4411	As	_	_	
44-2	4412-4413	a	_	_	
44-3	4414-4425	consequence	_	_	
44-4	4425-4426	,	_	_	
44-5	4427-4430	the	_	_	
44-6	4431-4435	mean	_	_	
44-7	4436-4445	residence	_	_	
44-8	4446-4450	time	_	_	
44-9	4451-4453	of	_	_	
44-10	4454-4457	the	_	_	
44-11	4458-4470	anti-mitotic	_	_	
44-12	4471-4479	compound	_	_	
44-13	4480-4488	existing	_	_	
44-14	4489-4491	in	_	_	
44-15	4492-4495	the	_	_	
44-16	4496-4503	soluble	_	_	
44-17	4504-4509	state	_	_	
44-18	4510-4512	is	_	_	
44-19	4513-4519	longer	_	_	
44-20	4520-4523	for	_	_	
44-21	4524-4525	a	_	_	
44-22	4526-4543	non-biodegradable	_	_	
44-23	4544-4550	matrix	_	_	
44-24	4551-4555	than	_	_	
44-25	4556-4559	for	_	_	
44-26	4560-4561	a	_	_	
44-27	4562-4575	biodegradable	_	_	
44-28	4576-4582	matrix	_	_	
44-29	4583-4588	where	_	_	
44-30	4589-4590	a	_	_	
44-31	4591-4595	long	_	_	
44-32	4596-4603	passage	_	_	
44-33	4604-4611	through	_	_	
44-34	4612-4615	the	_	_	
44-35	4616-4624	channels	_	_	
44-36	4625-4627	is	_	_	
44-37	4628-4630	no	_	_	
44-38	4631-4637	longer	_	_	
44-39	4638-4646	required	_	_	
44-40	4646-4647	.	_	_	

#Text=Since many pharmaceuticals have short half-lives it is likely that the anti-mitotic compound is decomposed or inactivated inside the non-biodegradable matrix before it can be released.
45-1	4648-4653	Since	_	_	
45-2	4654-4658	many	_	_	
45-3	4659-4674	pharmaceuticals	_	_	
45-4	4675-4679	have	_	_	
45-5	4680-4685	short	_	_	
45-6	4686-4696	half-lives	_	_	
45-7	4697-4699	it	_	_	
45-8	4700-4702	is	_	_	
45-9	4703-4709	likely	_	_	
45-10	4710-4714	that	_	_	
45-11	4715-4718	the	_	_	
45-12	4719-4731	anti-mitotic	_	_	
45-13	4732-4740	compound	_	_	
45-14	4741-4743	is	_	_	
45-15	4744-4754	decomposed	_	_	
45-16	4755-4757	or	_	_	
45-17	4758-4769	inactivated	_	_	
45-18	4770-4776	inside	_	_	
45-19	4777-4780	the	_	_	
45-20	4781-4798	non-biodegradable	_	_	
45-21	4799-4805	matrix	_	_	
45-22	4806-4812	before	_	_	
45-23	4813-4815	it	_	_	
45-24	4816-4819	can	_	_	
45-25	4820-4822	be	_	_	
45-26	4823-4831	released	_	_	
45-27	4831-4832	.	_	_	

#Text=This issue is particularly significant for many bio-macromolecules and smaller polypeptides, since these molecules are generally unstable in buffer and have low permeability through polymers in fact, in a non-biodegradable matrix, many bio-macromolecules will aggregate and precipitate, clogging the channels necessary for diffusion out of the carrier matrix.
46-1	4833-4837	This	_	_	
46-2	4838-4843	issue	_	_	
46-3	4844-4846	is	_	_	
46-4	4847-4859	particularly	_	_	
46-5	4860-4871	significant	_	_	
46-6	4872-4875	for	_	_	
46-7	4876-4880	many	_	_	
46-8	4881-4899	bio-macromolecules	_	_	
46-9	4900-4903	and	_	_	
46-10	4904-4911	smaller	_	_	
46-11	4912-4924	polypeptides	_	_	
46-12	4924-4925	,	_	_	
46-13	4926-4931	since	_	_	
46-14	4932-4937	these	_	_	
46-15	4938-4947	molecules	_	_	
46-16	4948-4951	are	_	_	
46-17	4952-4961	generally	_	_	
46-18	4962-4970	unstable	_	_	
46-19	4971-4973	in	_	_	
46-20	4974-4980	buffer	_	_	
46-21	4981-4984	and	_	_	
46-22	4985-4989	have	_	_	
46-23	4990-4993	low	_	_	
46-24	4994-5006	permeability	_	_	
46-25	5007-5014	through	_	_	
46-26	5015-5023	polymers	_	_	
46-27	5024-5026	in	_	_	
46-28	5027-5031	fact	_	_	
46-29	5031-5032	,	_	_	
46-30	5033-5035	in	_	_	
46-31	5036-5037	a	_	_	
46-32	5038-5055	non-biodegradable	_	_	
46-33	5056-5062	matrix	_	_	
46-34	5062-5063	,	_	_	
46-35	5064-5068	many	_	_	
46-36	5069-5087	bio-macromolecules	_	_	
46-37	5088-5092	will	_	_	
46-38	5093-5102	aggregate	_	_	
46-39	5103-5106	and	_	_	
46-40	5107-5118	precipitate	_	_	
46-41	5118-5119	,	_	_	
46-42	5120-5128	clogging	_	_	
46-43	5129-5132	the	_	_	
46-44	5133-5141	channels	_	_	
46-45	5142-5151	necessary	_	_	
46-46	5152-5155	for	_	_	
46-47	5156-5165	diffusion	_	_	
46-48	5166-5169	out	_	_	
46-49	5170-5172	of	_	_	
46-50	5173-5176	the	_	_	
46-51	5177-5184	carrier	_	_	
46-52	5185-5191	matrix	_	_	
46-53	5191-5192	.	_	_	

#Text=This problem is largely alleviated by using a biodegradable matrix which allows controlled release of the therapeutic agent.
47-1	5193-5197	This	*[2]	_	
47-2	5198-5205	problem	*[2]	_	
47-3	5206-5208	is	_	_	
47-4	5209-5216	largely	_	_	
47-5	5217-5227	alleviated	_	_	
47-6	5228-5230	by	_	_	
47-7	5231-5236	using	_	_	
47-8	5237-5238	a	_	_	
47-9	5239-5252	biodegradable	_	_	
47-10	5253-5259	matrix	_	_	
47-11	5260-5265	which	_	_	
47-12	5266-5272	allows	_	_	
47-13	5273-5283	controlled	_	_	
47-14	5284-5291	release	_	_	
47-15	5292-5294	of	_	_	
47-16	5295-5298	the	_	_	
47-17	5299-5310	therapeutic	_	_	
47-18	5311-5316	agent	_	_	
47-19	5316-5317	.	_	_	

#Text=Biodegradable polymers differ from non-biodegradable polymers in that they are consumed or biodegraded during therapy.
48-1	5318-5331	Biodegradable	_	_	
48-2	5332-5340	polymers	_	_	
48-3	5341-5347	differ	_	_	
48-4	5348-5352	from	_	_	
48-5	5353-5370	non-biodegradable	_	_	
48-6	5371-5379	polymers	_	_	
48-7	5380-5382	in	_	_	
48-8	5383-5387	that	_	_	
48-9	5388-5392	they	_	_	
48-10	5393-5396	are	_	_	
48-11	5397-5405	consumed	_	_	
48-12	5406-5408	or	_	_	
48-13	5409-5420	biodegraded	_	_	
48-14	5421-5427	during	_	_	
48-15	5428-5435	therapy	_	_	
48-16	5435-5436	.	_	_	

#Text=This usually involves breakdown of the polymer to its monomeric subunits, which should be biocompatible with the surrounding tissue.
49-1	5437-5441	This	_	_	
49-2	5442-5449	usually	_	_	
49-3	5450-5458	involves	_	_	
49-4	5459-5468	breakdown	_	_	
49-5	5469-5471	of	_	_	
49-6	5472-5475	the	_	_	
49-7	5476-5483	polymer	_	_	
49-8	5484-5486	to	_	_	
49-9	5487-5490	its	_	_	
49-10	5491-5500	monomeric	_	_	
49-11	5501-5509	subunits	_	_	
49-12	5509-5510	,	_	_	
49-13	5511-5516	which	_	_	
49-14	5517-5523	should	_	_	
49-15	5524-5526	be	_	_	
49-16	5527-5540	biocompatible	_	_	
49-17	5541-5545	with	_	_	
49-18	5546-5549	the	_	_	
49-19	5550-5561	surrounding	_	_	
49-20	5562-5568	tissue	_	_	
49-21	5568-5569	.	_	_	

#Text=The life of a biodegradable polymer in vivo depends on its molecular weight and degree of cross-linking; the greater the molecular weight and degree of crosslinking, the longer the life.
50-1	5570-5573	The	_	_	
50-2	5574-5578	life	_	_	
50-3	5579-5581	of	_	_	
50-4	5582-5583	a	_	_	
50-5	5584-5597	biodegradable	_	_	
50-6	5598-5605	polymer	_	_	
50-7	5606-5608	in	_	_	
50-8	5609-5613	vivo	_	_	
50-9	5614-5621	depends	_	_	
50-10	5622-5624	on	_	_	
50-11	5625-5628	its	_	_	
50-12	5629-5638	molecular	_	_	
50-13	5639-5645	weight	_	_	
50-14	5646-5649	and	_	_	
50-15	5650-5656	degree	_	_	
50-16	5657-5659	of	_	_	
50-17	5660-5673	cross-linking	_	_	
50-18	5673-5674	;	_	_	
50-19	5675-5678	the	_	_	
50-20	5679-5686	greater	_	_	
50-21	5687-5690	the	_	_	
50-22	5691-5700	molecular	_	_	
50-23	5701-5707	weight	_	_	
50-24	5708-5711	and	_	_	
50-25	5712-5718	degree	_	_	
50-26	5719-5721	of	_	_	
50-27	5722-5734	crosslinking	_	_	
50-28	5734-5735	,	_	_	
50-29	5736-5739	the	_	_	
50-30	5740-5746	longer	_	_	
50-31	5747-5750	the	_	_	
50-32	5751-5755	life	_	_	
50-33	5755-5756	.	_	_	

#Text=The most highly investigated biodegradable polymers are polylactic acid (PLA), polyglycolic acid (PGA), polyglycolic acid (PGA), copolymers of PLA and PGA, polyamides, and copolymers of polyamides and polyesters.
51-1	5757-5760	The	_	_	
51-2	5761-5765	most	_	_	
51-3	5766-5772	highly	_	_	
51-4	5773-5785	investigated	_	_	
51-5	5786-5799	biodegradable	_	_	
51-6	5800-5808	polymers	_	_	
51-7	5809-5812	are	_	_	
51-8	5813-5823	polylactic	_	_	
51-9	5824-5828	acid	_	_	
51-10	5829-5830	(	_	_	
51-11	5830-5833	PLA	_	_	
51-12	5833-5834	)	_	_	
51-13	5834-5835	,	_	_	
51-14	5836-5848	polyglycolic	_	_	
51-15	5849-5853	acid	_	_	
51-16	5854-5855	(	_	_	
51-17	5855-5858	PGA	_	_	
51-18	5858-5859	)	_	_	
51-19	5859-5860	,	_	_	
51-20	5861-5873	polyglycolic	_	_	
51-21	5874-5878	acid	_	_	
51-22	5879-5880	(	_	_	
51-23	5880-5883	PGA	_	_	
51-24	5883-5884	)	_	_	
51-25	5884-5885	,	_	_	
51-26	5886-5896	copolymers	_	_	
51-27	5897-5899	of	_	_	
51-28	5900-5903	PLA	_	_	
51-29	5904-5907	and	_	_	
51-30	5908-5911	PGA	_	_	
51-31	5911-5912	,	_	_	
51-32	5913-5923	polyamides	_	_	
51-33	5923-5924	,	_	_	
51-34	5925-5928	and	_	_	
51-35	5929-5939	copolymers	_	_	
51-36	5940-5942	of	_	_	
51-37	5943-5953	polyamides	_	_	
51-38	5954-5957	and	_	_	
51-39	5958-5968	polyesters	_	_	
51-40	5968-5969	.	_	_	

#Text=PLA, sometimes referred to as polylactide, undergoes hydrolytic de-esterification to lactic acid, a normal product of muscle metabolism.
52-1	5970-5973	PLA	_	_	
52-2	5973-5974	,	_	_	
52-3	5975-5984	sometimes	_	_	
52-4	5985-5993	referred	_	_	
52-5	5994-5996	to	_	_	
52-6	5997-5999	as	_	_	
52-7	6000-6011	polylactide	_	_	
52-8	6011-6012	,	_	_	
52-9	6013-6022	undergoes	_	_	
52-10	6023-6033	hydrolytic	_	_	
52-11	6034-6051	de-esterification	_	_	
52-12	6052-6054	to	_	_	
52-13	6055-6061	lactic	_	_	
52-14	6062-6066	acid	_	_	
52-15	6066-6067	,	_	_	
52-16	6068-6069	a	_	_	
52-17	6070-6076	normal	_	_	
52-18	6077-6084	product	_	_	
52-19	6085-6087	of	_	_	
52-20	6088-6094	muscle	_	_	
52-21	6095-6105	metabolism	_	_	
52-22	6105-6106	.	_	_	

#Text=PGA is chemically related to PLA and is commonly used for absorbable surgical sutures, as is the PLA/PGA copolymer.
53-1	6107-6110	PGA	_	_	
53-2	6111-6113	is	_	_	
53-3	6114-6124	chemically	_	_	
53-4	6125-6132	related	_	_	
53-5	6133-6135	to	_	_	
53-6	6136-6139	PLA	_	_	
53-7	6140-6143	and	_	_	
53-8	6144-6146	is	_	_	
53-9	6147-6155	commonly	_	_	
53-10	6156-6160	used	_	_	
53-11	6161-6164	for	_	_	
53-12	6165-6175	absorbable	_	_	
53-13	6176-6184	surgical	_	_	
53-14	6185-6192	sutures	_	_	
53-15	6192-6193	,	_	_	
53-16	6194-6196	as	_	_	
53-17	6197-6199	is	_	_	
53-18	6200-6203	the	_	_	
53-19	6204-6207	PLA	_	_	
53-20	6207-6208	/	_	_	
53-21	6208-6211	PGA	_	_	
53-22	6212-6221	copolymer	_	_	
53-23	6221-6222	.	_	_	

#Text=However, the use of PGA in controlled-release implants has been limited due to its low solubility in common solvents and subsequent difficulty in fabrication of devices."
54-1	6223-6230	However	_	_	
54-2	6230-6231	,	_	_	
54-3	6232-6235	the	_	_	
54-4	6236-6239	use	_	_	
54-5	6240-6242	of	_	_	
54-6	6243-6246	PGA	_	_	
54-7	6247-6249	in	_	_	
54-8	6250-6268	controlled-release	_	_	
54-9	6269-6277	implants	_	_	
54-10	6278-6281	has	_	_	
54-11	6282-6286	been	_	_	
54-12	6287-6294	limited	_	_	
54-13	6295-6298	due	_	_	
54-14	6299-6301	to	_	_	
54-15	6302-6305	its	_	_	
54-16	6306-6309	low	_	_	
54-17	6310-6320	solubility	_	_	
54-18	6321-6323	in	_	_	
54-19	6324-6330	common	_	_	
54-20	6331-6339	solvents	_	_	
54-21	6340-6343	and	_	_	
54-22	6344-6354	subsequent	_	_	
54-23	6355-6365	difficulty	_	_	
54-24	6366-6368	in	_	_	
54-25	6369-6380	fabrication	_	_	
54-26	6381-6383	of	_	_	
54-27	6384-6391	devices	_	_	
54-28	6391-6392	.	_	_	
54-29	6392-6393	"	_	_	

#Text=The polymeric material 14 may be a biodegradable polymeric material.
#Text=[0559] U.S.
55-1	6394-6397	The	_	_	
55-2	6398-6407	polymeric	_	_	
55-3	6408-6416	material	_	_	
55-4	6417-6419	14	_	_	
55-5	6420-6423	may	_	_	
55-6	6424-6426	be	_	_	
55-7	6427-6428	a	_	_	
55-8	6429-6442	biodegradable	_	_	
55-9	6443-6452	polymeric	_	_	
55-10	6453-6461	material	_	_	
55-11	6461-6462	.	_	_	
55-12	6463-6464	[	_	_	
55-13	6464-6468	0559	_	_	
55-14	6468-6469	]	_	_	
55-15	6470-6473	U.S	_	_	
55-16	6473-6474	.	_	_	

#Text=Pat.
56-1	6475-6478	Pat	_	_	
56-2	6478-6479	.	_	_	

#Text=No. 5,176,907 also discloses "An advantage of a biodegradable material is the elimination of the need for surgical removal after it has fulfilled its mission.
57-1	6480-6482	No	_	_	
57-2	6482-6483	.	_	_	
57-3	6484-6493	5,176,907	_	_	
57-4	6494-6498	also	_	_	
57-5	6499-6508	discloses	_	_	
57-6	6509-6510	"	_	_	
57-7	6510-6512	An	_	_	
57-8	6513-6522	advantage	_	_	
57-9	6523-6525	of	_	_	
57-10	6526-6527	a	_	_	
57-11	6528-6541	biodegradable	_	_	
57-12	6542-6550	material	_	_	
57-13	6551-6553	is	_	_	
57-14	6554-6557	the	_	_	
57-15	6558-6569	elimination	_	_	
57-16	6570-6572	of	_	_	
57-17	6573-6576	the	_	_	
57-18	6577-6581	need	_	_	
57-19	6582-6585	for	_	_	
57-20	6586-6594	surgical	_	_	
57-21	6595-6602	removal	_	_	
57-22	6603-6608	after	_	_	
57-23	6609-6611	it	_	_	
57-24	6612-6615	has	_	_	
57-25	6616-6625	fulfilled	_	_	
57-26	6626-6629	its	_	_	
57-27	6630-6637	mission	_	_	
57-28	6637-6638	.	_	_	

#Text=The appeal of such a material is more than simply for convenience.
58-1	6639-6642	The	_	_	
58-2	6643-6649	appeal	_	_	
58-3	6650-6652	of	_	_	
58-4	6653-6657	such	_	_	
58-5	6658-6659	a	_	_	
58-6	6660-6668	material	_	_	
58-7	6669-6671	is	_	_	
58-8	6672-6676	more	_	_	
58-9	6677-6681	than	_	_	
58-10	6682-6688	simply	_	_	
58-11	6689-6692	for	_	_	
58-12	6693-6704	convenience	_	_	
58-13	6704-6705	.	_	_	

#Text=From a technical standpoint, a material which biodegrades gradually and is excreted over time can offer many unique advantages."
#Text=[0560] U.S.
59-1	6706-6710	From	_	_	
59-2	6711-6712	a	_	_	
59-3	6713-6722	technical	_	_	
59-4	6723-6733	standpoint	_	_	
59-5	6733-6734	,	_	_	
59-6	6735-6736	a	_	_	
59-7	6737-6745	material	_	_	
59-8	6746-6751	which	_	_	
59-9	6752-6763	biodegrades	_	_	
59-10	6764-6773	gradually	_	_	
59-11	6774-6777	and	_	_	
59-12	6778-6780	is	_	_	
59-13	6781-6789	excreted	_	_	
59-14	6790-6794	over	_	_	
59-15	6795-6799	time	_	_	
59-16	6800-6803	can	_	_	
59-17	6804-6809	offer	_	_	
59-18	6810-6814	many	_	_	
59-19	6815-6821	unique	_	_	
59-20	6822-6832	advantages	_	_	
59-21	6832-6833	.	_	_	
59-22	6833-6834	"	_	_	
59-23	6835-6836	[	_	_	
59-24	6836-6840	0560	_	_	
59-25	6840-6841	]	_	_	
59-26	6842-6845	U.S	_	_	
59-27	6845-6846	.	_	_	

#Text=Pat.
60-1	6847-6850	Pat	_	_	
60-2	6850-6851	.	_	_	

#Text=No. 5,176,907 also discloses "A biodegradable thereapeutic agent delivery system has several additional advantages: 1) the therapeutic agent release rate is amenable to control through variation of the matrix composition; 2) implantation can be done at sites difficult or impossible for retrieval; 3) delivery of unstable therapeutic agents is more practical.
61-1	6852-6854	No	_	_	
61-2	6854-6855	.	_	_	
61-3	6856-6865	5,176,907	_	_	
61-4	6866-6870	also	_	_	
61-5	6871-6880	discloses	_	_	
61-6	6881-6882	"	_	_	
61-7	6882-6883	A	_	_	
61-8	6884-6897	biodegradable	_	_	
61-9	6898-6910	thereapeutic	_	_	
61-10	6911-6916	agent	_	_	
61-11	6917-6925	delivery	_	_	
61-12	6926-6932	system	_	_	
61-13	6933-6936	has	_	_	
61-14	6937-6944	several	_	_	
61-15	6945-6955	additional	_	_	
61-16	6956-6966	advantages	_	_	
61-17	6966-6967	:	_	_	
61-18	6968-6969	1	_	_	
61-19	6969-6970	)	_	_	
61-20	6971-6974	the	_	_	
61-21	6975-6986	therapeutic	_	_	
61-22	6987-6992	agent	_	_	
61-23	6993-7000	release	_	_	
61-24	7001-7005	rate	_	_	
61-25	7006-7008	is	_	_	
61-26	7009-7017	amenable	_	_	
61-27	7018-7020	to	_	_	
61-28	7021-7028	control	_	_	
61-29	7029-7036	through	_	_	
61-30	7037-7046	variation	_	_	
61-31	7047-7049	of	_	_	
61-32	7050-7053	the	_	_	
61-33	7054-7060	matrix	_	_	
61-34	7061-7072	composition	_	_	
61-35	7072-7073	;	_	_	
61-36	7074-7075	2	_	_	
61-37	7075-7076	)	_	_	
61-38	7077-7089	implantation	_	_	
61-39	7090-7093	can	_	_	
61-40	7094-7096	be	_	_	
61-41	7097-7101	done	_	_	
61-42	7102-7104	at	_	_	
61-43	7105-7110	sites	_	_	
61-44	7111-7120	difficult	_	_	
61-45	7121-7123	or	_	_	
61-46	7124-7134	impossible	_	_	
61-47	7135-7138	for	_	_	
61-48	7139-7148	retrieval	_	_	
61-49	7148-7149	;	_	_	
61-50	7150-7151	3	_	_	
61-51	7151-7152	)	_	_	
61-52	7153-7161	delivery	_	_	
61-53	7162-7164	of	_	_	
61-54	7165-7173	unstable	_	_	
61-55	7174-7185	therapeutic	_	_	
61-56	7186-7192	agents	_	_	
61-57	7193-7195	is	_	_	
61-58	7196-7200	more	_	_	
61-59	7201-7210	practical	_	_	
61-60	7210-7211	.	_	_	

#Text=This last point is of particular importance in light of the advances in molecular biology and genetic engineering which have lead to the commercial availability of many potent bio-macromolecules.
62-1	7212-7216	This	_	_	
62-2	7217-7221	last	_	_	
62-3	7222-7227	point	_	_	
62-4	7228-7230	is	_	_	
62-5	7231-7233	of	_	_	
62-6	7234-7244	particular	_	_	
62-7	7245-7255	importance	_	_	
62-8	7256-7258	in	_	_	
62-9	7259-7264	light	_	_	
62-10	7265-7267	of	_	_	
62-11	7268-7271	the	_	_	
62-12	7272-7280	advances	_	_	
62-13	7281-7283	in	_	_	
62-14	7284-7293	molecular	_	_	
62-15	7294-7301	biology	_	_	
62-16	7302-7305	and	_	_	
62-17	7306-7313	genetic	_	_	
62-18	7314-7325	engineering	_	_	
62-19	7326-7331	which	_	_	
62-20	7332-7336	have	_	_	
62-21	7337-7341	lead	_	_	
62-22	7342-7344	to	_	_	
62-23	7345-7348	the	_	_	
62-24	7349-7359	commercial	_	_	
62-25	7360-7372	availability	_	_	
62-26	7373-7375	of	_	_	
62-27	7376-7380	many	_	_	
62-28	7381-7387	potent	_	_	
62-29	7388-7406	bio-macromolecules	_	_	
62-30	7406-7407	.	_	_	

#Text=The short in vivo half-lives and low GI tract absorption of these polypeptides render them totally unsuitable for conventional oral or intravenous administration.
63-1	7408-7411	The	_	_	
63-2	7412-7417	short	_	_	
63-3	7418-7420	in	_	_	
63-4	7421-7425	vivo	_	_	
63-5	7426-7436	half-lives	_	_	
63-6	7437-7440	and	_	_	
63-7	7441-7444	low	_	_	
63-8	7445-7447	GI	_	_	
63-9	7448-7453	tract	_	_	
63-10	7454-7464	absorption	_	_	
63-11	7465-7467	of	_	_	
63-12	7468-7473	these	_	_	
63-13	7474-7486	polypeptides	_	_	
63-14	7487-7493	render	_	_	
63-15	7494-7498	them	_	_	
63-16	7499-7506	totally	_	_	
63-17	7507-7517	unsuitable	_	_	
63-18	7518-7521	for	_	_	
63-19	7522-7534	conventional	_	_	
63-20	7535-7539	oral	_	_	
63-21	7540-7542	or	_	_	
63-22	7543-7554	intravenous	_	_	
63-23	7555-7569	administration	_	_	
63-24	7569-7570	.	_	_	

#Text=Also, because these substances are often unstable in buffer, such polypeptides cannot be effectively delivered by pumping devices."
64-1	7571-7575	Also	_	_	
64-2	7575-7576	,	_	_	
64-3	7577-7584	because	_	_	
64-4	7585-7590	these	_	_	
64-5	7591-7601	substances	_	_	
64-6	7602-7605	are	_	_	
64-7	7606-7611	often	_	_	
64-8	7612-7620	unstable	_	_	
64-9	7621-7623	in	_	_	
64-10	7624-7630	buffer	_	_	
64-11	7630-7631	,	_	_	
64-12	7632-7636	such	_	_	
64-13	7637-7649	polypeptides	_	_	
64-14	7650-7656	cannot	_	_	
64-15	7657-7659	be	_	_	
64-16	7660-7671	effectively	_	_	
64-17	7672-7681	delivered	_	_	
64-18	7682-7684	by	_	_	
64-19	7685-7692	pumping	_	_	
64-20	7693-7700	devices	_	_	
64-21	7700-7701	.	_	_	
64-22	7701-7702	"	_	_	
